Clinical and pre-clinical data from across the company’s hematopoietic stem cell (HSC) gene therapy portfolio will be featured in two oral and seven poster presentations, including an update on the ongoing proof-of-concept study of OTL-201 for the treatment of Mucopolysaccharidosis type
Additionally, Orchard’s scientific advisory board member and clinical collaborator
The presentations are listed below, and the full program is available online on the ESGCT website. All times are Central European
Oral Presentation Details:
Haematopoietic reconstitution dynamics of mobilized peripheral blood- and bone marrow-derived haematopoietic stem/progenitor cells after gene therapy
Presenting Author:
Abstract Number: OR049
Date/Time:
Longitudinal monitoring of vector integration sites in in vivo GT approaches by Liquid-Biopsy-Integration-Site-Sequencing
Presenting Author:
Abstract Number: OR058
Date/Time:
Poster Presentation Details:
All posters will be available on demand starting
Development of an ex vivo Gene Therapy for Frontotemporal Dementia (FTD)
Presenting Author:
Abstract Number: P077
Optimized Lentiviral Transduction Process for ex vivo CD34+ Hematopoietic Stem Cell Gene Therapy Drug Product Manufacture
Presenting Author:
Abstract Number: P271
Clinical Trial Update: Ex-vivo autologous stem cell gene therapy in MPSIIIA
Presenting Author:
Abstract Number: P361
Dissecting bone remodelling mechanisms and hematopoietic stem cell gene therapy impact in Mucopolysaccharidosis type I Hurler bone defects
Presenting Author:
Abstract Number: P157
Hematopoietic reconstitution and lineage commitment in HSC GT patients are influenced by the disease background
Presenting Author:
Abstract Number: P181
Kinetics and composition of haematopoietic stem/progenitors mobilized cells upon G-CSF and Plerixafor administration in transplant donor or patients undergoing autologous gene therapy
Presenting Author:
Abstract Number: P174
Role of peripheral blood circulating haematopoietic stem/progenitor cells during physiological haematopoietic maturation and after gene therapy
Presenting Author:
Abstract Number: P186
About
At
In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the
Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Availability of Other Information About Orchard
Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Contacts
Investors
Director, Investor Relations
+1 862-242-0764
Renee.Leck@orchard-tx.com
Media
Director, Corporate Communications
+1 857-248-9454
Benjamin.Navon@orchard-tx.com
Source:
2021 GlobeNewswire, Inc., source